Arianayagam Ranjan, Arianayagam Mohan, Rashid Prem
Royal North Shore Hospital, Sydney, New South Wales.
Aust Fam Physician. 2011 Apr;40(4):209-13.
Over 2000 cases of bladder cancer were diagnosed in Australia in 2005. Bladder cancer is a relatively common disease with high morbidity if left untreated. Bladder cancer is categorised as either 'nonmuscle invasive bladder cancer' or 'muscle invasive bladder cancer'. Treatment varies significantly for each type.
This article provides an update on the presentation of bladder cancer, its risk factors, investigations and treatment, and discusses the role of chemotherapy as a neoadjuvant and adjuvant treatment.
Bladder cancer most commonly presents with microscopic or macroscopic haematuria. Evaluation is required of all patients with macroscopic haematuria, patients with persistent microscopic haematuria, and at risk patients with a single episode of microscopic haematuria. Evaluation consists of imaging, urine cytology and cystoscopy. Nonmuscle invasive bladder cancer patients can undergo tumour resection with adjuvant intravesical treatments, while muscle invasive bladder cancer patients are optimally treated with cystectomy and urinary diversion.
2005年澳大利亚诊断出2000多例膀胱癌病例。膀胱癌是一种相对常见的疾病,如果不治疗,发病率很高。膀胱癌分为“非肌层浸润性膀胱癌”或“肌层浸润性膀胱癌”。每种类型的治疗方法差异很大。
本文提供了膀胱癌的临床表现、危险因素、检查和治疗的最新情况,并讨论了化疗作为新辅助和辅助治疗的作用。
膀胱癌最常见的表现是镜下或肉眼血尿。所有肉眼血尿患者、持续性镜下血尿患者以及有单次镜下血尿发作风险的患者都需要进行评估。评估包括影像学检查、尿液细胞学检查和膀胱镜检查。非肌层浸润性膀胱癌患者可接受肿瘤切除并辅助膀胱内治疗,而肌层浸润性膀胱癌患者最佳的治疗方法是膀胱切除术和尿流改道。